NCT04203160View on ClinicalTrials.gov

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

April 16, 2024

Study Completion Date

April 29, 2024

Conditions
Biliary Tract Cancer
Interventions
DRUG

CPI 613

Given intravenously

DRUG

Gemcitabine

Given intravenously

DRUG

Cisplatin

Given intravenously

Trial Locations (10)

15224

Allegheny Health Network, Pittsburgh

37232

Vanderbilt-Ingram Cancer Center, Nashville

44106

University Hospitals - Seidman Cancer Center, Cleveland

48109

University of Michigan Rogel Cancer Center, Ann Arbor

53705

University of Wisconsin - Carbone Cancer Center, Madison

60611

Northwestern University -- Lurie Comprehensive Cancer Center, Chicago

75390

University of Texas Southwestern -- Simmons Comprehensive Cancer Center, Dallas

85724

University of Arizona Cancer Center, Tucson

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

07960

Atlantic Health System, Morristown

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT04203160 - Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | Biotech Hunter | Biotech Hunter